July 25, 2014 - Recent coverage in the local business journal of SenGenix and Aerie, two healthcare businesses created by Duke facultyJuly 25, 2014
The Triangle Business Journal recently covered news about two companies spun out of Duke that hope to bring new treatments and tools to health care.
SenGenix, a small company led by Richard Surwit, a professor of Psychiatry and Behavioral Sciences, is working on improving technology in point-of-care diagnostics. Current technology for in vitro diagnostics -- tests done outside the body -- run in the $10,000 to $12,000 range. SenGenix plans to use new camera technology and advances in biochemistry to develop less costly devices. The company plans to have a prototype available in a few months, at which point hte team will look to find a larger company to partner with or gain a larger investment from a venture capital firm.
Aerie Pharmaceuticals, another Duke spinout, has received permission to begin testing its glaucoma treatment in Canada. If approved, the new treatment, called Rhopressa, would be the only once-daily product available that specifically targets the trabecular meshwork, the eye's primary fluid drain and the diseased tissue responsible for elevated eye pressure in glaucoma. Aerie has already started two trials of Rhopressa in the United States.